Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
about
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart LesionsDirect oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic reviewUsing an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age.Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanResolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review.Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives.Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.Apixaban to prevent stroke in patients with atrial fibrillation: a review.Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.The year in cardiology 2015: valvular heart disease.The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient.Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment: An Alternative Viewpoint.2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations.Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).2017 ESC/EACTS Guidelines for the management of valvular heart disease.Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.Poor outcomes associated with antithrombotic undertreatment in patients with atrial fibrillation attending Gondar University Hospital: a retrospective cohort studyOral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
P2860
Q26764853-C67DC97C-5A19-472C-A8BB-3E92D9976CB2Q28071807-20421352-4BD9-46EC-85C5-C27D6DB5AA34Q36951700-B3F2AF4E-486F-4027-8717-25B6308E6076Q37085638-808B8DD6-437C-4033-A9B0-1956364BFE1BQ37606144-5F8BBD5C-65AC-49F6-B9E8-0B736904DEC2Q38384634-64D000F1-A6EC-4820-BA7F-3FF47EA17D26Q38635568-F0B2BD7E-F7D1-40B3-B0DF-5A321F6E7076Q38647787-CB7E6A2E-0548-46D2-8C70-8C16DB23F8BEQ38650658-7731678D-C054-45E4-AF92-3D7060D112DDQ38673244-D69F790A-D641-400B-A57C-0B405AB5139FQ38723866-C8862982-5970-487D-9A5F-BC7F2E53984AQ38860492-AECBBA21-5286-458D-966E-BE3EC5E38CECQ38876376-B94F0293-99FE-4E9D-84B1-AE3C371AAF62Q38963690-D3488135-725A-4D94-A6CB-A311B30F3449Q39612619-3C990C8B-B3D1-415D-81C5-8627D9D1D97BQ40461490-D295406E-3E00-413C-B1CD-02DEC2B63A78Q40847130-428BFDD8-8E7D-48C1-94CD-6782D70688D3Q47118947-557B5EC0-565C-4B92-8C7F-FF3D2307CC8CQ47245138-F71405FD-95AE-4BE9-B7CD-212DE3795258Q47654635-253B56B9-CDCA-4AC4-BE30-E64D5513742FQ47918560-495C6FB6-680A-4071-9AFA-EDB3EABAC8AEQ48351747-AADC532E-691C-46CE-8602-5B51AADC7AF1Q49516122-37AEFA4E-42B0-4B74-9EB9-BB2AF53AB33DQ49607144-94B225BA-E8BD-4D78-885E-06B104B6B708Q50196541-A339FCE5-A219-4390-82D8-2926DFABD746Q52603887-25A07B60-F9F6-4478-85BA-ECD87FABED63Q58727771-FD9565C7-037E-47DC-BE2C-B27390885077Q58781692-2B71B272-7CAA-4BD6-8F3B-D3747180ECF7
P2860
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Apixaban in Comparison With Wa ...... ibrillation (ARISTOTLE) Trial.
@en
type
label
Apixaban in Comparison With Wa ...... ibrillation (ARISTOTLE) Trial.
@en
prefLabel
Apixaban in Comparison With Wa ...... ibrillation (ARISTOTLE) Trial.
@en
P2093
P1433
P1476
Apixaban in Comparison With Wa ...... ibrillation (ARISTOTLE) Trial.
@en
P2093
Alvaro Avezum
Bernard J Gersh
Cetin Erol
Fernando Lanas
John H Alexander
Jozef Bartunek
M Cecilia Bahit
Michael Hanna
Phillip J Schulte
P304
P356
10.1161/CIRCULATIONAHA.114.014807
P407
P577
2015-06-23T00:00:00Z